US 7943626
Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase
granted A61PA61P1/04A61P1/18
Quick answer
US patent 7943626 (Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase) held by Takeda Pharmaceutical Company Limited expires Mon May 12 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue May 17 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 12 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61P, A61P1/04, A61P1/18, A61P11/06, A61P13/12